PD-1 (Programmed Cell Death Protein-1) and PD-L1 (Programmed Cell Death Ligand-1)
play a crucial role in regulating the immune system and preventing autoimmunity. Cancer …

Immune checkpoint blockade (ICB) therapies such as anti-programmed death 1 (PD-1) and
anti-CTLA-4 (cytotoxic T lymphocyte-associated protein 4) have dramatically transformed …

Background: Inhibitors targeting programmed cell death 1 (PD-1) and programmed death-
ligand 1 (PD-L1) have unprecedented effects in cancer treatment. However, the objective …

Peripheral T-cell lymphomas (PTCL), a heterogeneous group of mature aggressive non-
Hodgkin's lymphomas, carry a worse prognosis for most subtypes when compared with their …

Peripheral T cell lymphomas (PTCLs) are a heterogeneous group of orphan neoplasms.
Despite the introduction of anthracycline-based chemotherapy protocols, with or without …

Non-Hodgkin lymphomas represents a heterogeneous group of lymphoproliferative
disorders characterized by different clinical courses, varying from indolent to highly …

Abstract Purpose of Review Programmed cell death protein-1 (PD-1) is currently the most
extensively studied inhibitory checkpoint molecule. Many malignant neoplasms express the …

Over the last two decades, several epi‐drugs, immune checkpoint inhibitors (ICIs) and
adoptive cell therapies have received clinical approval for use in certain types of cancer …

Historical advances in the care of patients with non‐Hodgkin lymphoma (NHL) have been
restricted largely to patients with B‐cell lymphoma. The peripheral T‐cell lymphomas …

This phase I, dose-escalation trial evaluates the safety of combining interferon-gamma (IFN-
γ) and nivolumab in patients with metastatic solid tumors. Twenty-six patients are treated in …